Abstract
Background: 18F-fluorodeoxyglucose positron emission tomography integrated with computed tomography (18-F-FDG-PET/CT) is getting wide consensus in the diagnosis and staging of neoplastic disorders and represents a useful tool in the assessment of various inflammatory conditions.
Discussion: Sarcoidosis is an uncommon disease characterized by the systemic formation of noncaseating granulomas. Lungs are the sites most often affected, and investigation with high resolution computed tomography and biopsy is essential to achieve a correct diagnosis. 18-F-FDGPET/ CT is effective in the assessment of pulmonary sarcoidosis by demonstrating pulmonary and extrathoracic involvement and findings correlate well with pulmonary function in patients affected.
Conclusion: This review would illustrate the usefulness and limits of 18-F-FDG-PET/CT in the assessment of pulmonary sarcoidosis.
Keywords: Internist, pulmonary sarcoidosis, FDG-PET, CT, (HIV)-related infections, musculoskeletal infections.
[3]
Chokoeva AA, Tchernev G, Tana M, Tana C. Exclusion criteria for sarcoidosis: A novel approach for an ancient disease? Eur J Intern Med 2014; 25(10): e120.
[4]
Tana C, Wegener S, Borys E, et al. Challenges in the diagnosis and treatment of neurosarcoidosis. Ann Med 2015; 47(7): 576-91.
[5]
Brauner MW, Grenier P, Mompoint D, Lenoir S, de Crémoux H. Pulmonary sarcoidosis: Evaluation with high-resolution CT. Radiology 1989; 172(2): 467-71.
[6]
Müller NL, Kullnig P, Miller RR. The CT findings of pulmonary sarcoidosis: Analysis of 25 patients. AJR Am J Roentgenol 1989; 152(6): 1179-82.
[7]
Nishimura K, Itoh H, Kitaichi M, Nagai S, Izumi T. CT and pathological correlation of pulmonary sarcoidosis. Semin Ultrasound CT MR 1995; 16(5): 361-70.
[8]
Xaubet A, Ancochea J, Morell F, et al. Report on the incidence of interstitial lung diseases in Spain. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21(1): 64-70.
[9]
Siltzbach LE, James DG, Neville E, et al. Course and prognosis of sarcoidosis around the world. Am J Med 1974; 57(6): 847-52.
[10]
Bottaro L, Calderan L, Dibilio D, Mosconi E, Maffessanti M. Pulmonary sarcoidosis: Atypical HRTC features and differential diagnostic problems. Radiol Med 2004; 107(4): 273-85.
[11]
Miller BH, Rosado-de-christenson ML, Mcadams HP, et al. Thoracic sarcoidosis: Radiologic-pathologic correlation. Radiographics 1995; 15(2): 421-37.
[12]
Abehsera M, Valeyre D, Grenier P, et al. Sarcoidosis with pulmonary fibrosis: CT patterns and correlation with pulmonary function. AJR Am J Roentgenol 2000; 174: 1751-7.
[13]
Drent M, De Vries J, Lenters M, et al. Sarcoidosis: Assessment of disease severity using HRCT. Eur Radiol 2003; 13: 2462-71.
[14]
Teirstein AS, Machac J, Almeida O, et al. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest 2007; 132: 1949-53.
[15]
Keijsers RG, Verzijlbergen FJ, Oyen WJ, et al. 18F-FDG PET, genotypecorrected ACE and sIL-2R in newly diagnosed sarcoidosis. Eur J Nucl Med Mol Imaging 2009; 36: 1131-7.
[16]
Braun JJ, Kessler R, Constantinesco A, Imperiale A. 18F-FDG PET/CT in sarcoidosis management: Review and report of 20 cases. Eur J Nucl Med Mol Imaging 2008; 35: 1537-43.
[17]
Keijsers RG, Van den Heuvel DAF, Grutters JC. Imaging the inflammatory activity of sarcoidosis. Eur Respir J 2013; 41: 743-51.
[18]
Keijsers RG, Grutters JC, Thomeer M, et al. Imaging the inflammatory activity of sarcoidosis: Sensitivity and inter observer agreement of (67)Ga imaging and (18)F-FDG PET. Q J Nucl Med Mol Imaging 2011; 55: 66-71.
[19]
Mostard RL, van Kroonenburgh MJ, Drent M. The role of the PET scan in the management of sarcoidosis. Curr Opin Pulm Med 2013; 19(5): 538-44.
[20]
Guleria R, Jyothidasan A, Madan K, et al. Utility of FDG-PET-CT scanning in assessing the extent of disease activity and response to treatment in sarcoidosis. Lung India 2014; 31(4): 323-30.
[21]
Treglia G, Taralli S, Giordano A. Emerging role of whole-body 18F-fluorodeoxyglucose positron emission tomography as a marker of disease activity in patients with sarcoidosis: A systematic review. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28(2): 87-94.
[22]
Soussan M, Augier A, Brillet PY, Weinmann P, Valeyre D. Functional imaging in extrapulmonary sarcoidosis: FDG-PET/CT and MR features. Clin Nucl Med 2014; 39(2): e146-59.
[23]
Bastiaannet E, Uyl-de Groot CA, Brouwers AH, et al. Cost-effectiveness of adding FDG-PET or CT to the diagnostic work-up of patients with stage III melanoma. Ann Surg 2012; 255(4): 771-6.
[24]
Mana J, Salazar A, Manresa F. Clinical factors predicting persistence of activity in sarcoidosis: A multivariate analysis of 193 cases. Respiration 1994; 61(4): 219-25.
[25]
Keijsers RG, Verzijlbergen EJ, van den Bosch JM, et al. 18F-FDG PET as a predictor of pulmonary function in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28(2): 123-9.
[26]
Takada K, Ina Y, Noda M, Sato T, Yamamoto M, Morishita M. The clinical course and prognosis of patients with severe, moderate or mild sarcoidosis. J Clin Epidemiol 1993; 46(4): 359-66.
[27]
Brincker H. Coexistence of sarcoidosis and malignant disease: Causality or coincidence? Sarcoidosis 1989; 6: 31-43.
[28]
Caetano R, Schluckebier LF, Bastos CR, et al. Cost analysis of18F-FDG PET-CT from the perspective of the Brazilian unified national health system as healthcare provider: A study in a public healthcare center in Rio de Janeiro, Brazil. Cad Saude Publica 2014; 30(2): 379-92.
[29]
Keijsers RG, Verzijlbergen JF, van Diepen DM, van den Bosch JM, Grutters JC. 18F-FDG PET in sarcoidosis: An observational study in 12 patients treated with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 2008; 25(2): 143-9.
[30]
Brix G, Lechel U, Glatting G, et al. Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. J Nucl Med 2005; 46(4): 608-13.
[31]
Huang B, Law MW, Khong PL. Whole-body PET/CT scanning: Estimation of radiation dose and cancer risk. Radiology 2009; 251(1): 166-74.
[32]
Sobic-Saranovic D, Artiko V, Obradovic V. FDG PET imaging in sarcoidosis. Semin Nucl Med 2013; 43(6): 404-11.
[33]
Bichel J, Brincker H. Treatment of pruritus in Hodgkin’s disease and in reticulum cell sarcoma. Scand J Haematol 1965; 2: 85-90.
[34]
Juweid ME, Cheson BD. Role of positron emission tomography in lymphoma. J Clin Oncol 2005; 23: 4577-80.
[35]
JBasu S, Zhuang H, Torigian DA, et al Functional imaging of inflammatory diseases using nuclear medicine techniques. Semin Nucl Med 2009; 39: 124-45.
[36]
Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006; 354: 496-507.
[37]
Zhuang H, Alavi A. 18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med 2002; 32: 47-59.
[38]
Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med 1994; 35: 1647-9.
[39]
Kubota K, Itoh M, Ozaki K, et al. Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med 2001; 28: 696-703.
[40]
Kaneko M, Tomioka H, Kaneda T, et al. Value of 18F-fluorodeoxyglucose-PET in the diagonosis and monitoring of pulmonary sarcoidosis: A case report. Nihon Kokyuki Gakkai Zasshi 2008; 46(6): 505-9.
[41]
Yamada Y, Uchida Y, Tatsumi K, et al. Fluorine-18-fluorodeoxyglucose and carbon-11-methionine evaluation of lymphadenopathy in sarcoidosis. J Nucl Med 1998; 39: 1160-6.
[42]
Kis A, Eszes N, Tamasi L, et al. Sarcoidosis lymphoma syndrome - the value of PET-CT in the diagnosis. World J Surg Oncol 2013 18; 11: 235.
[43]
Brady B, Kamel D, Kiely J, Hennessy B. Dual diagnosis of sarcoidosis and lymphoma. Ir J Med Sci 2013; 182(2): 283-6.
[44]
Vaidyanathan S, Patel CN, Scarsbrook AF, Chowdhury FU. FDG PET/CT in infection and inflammation--current and emerging clinical applications. Clin Radiol 2015; 70(7): 787-800.
[45]
Grados A, Ebbo M, Bernit E, et al. Sarcoidosis occurring after solid cancer: A nonfortuitous association: Report of 12 cases and review of the literature. Medicine (Baltimore) 2015; 94(28): e928.
[46]
Chowdhury FU, Sheerin F, Bradley KM, Gleeson FV. Sarcoid-like reaction to malignancy on whole-body integrated (18)F-FDG PET/CT: Prevalence and disease pattern. Clin Radiol 2009; 64(7): 675-81.
[47]
Conte G, Zugni F, Colleoni M, Renne G, Bellomi M, Petralia G. Sarcoidosis with bone involvement mimicking metastatic disease at (18)F-FDG PET/CT: Problem solving by diffusion whole-body MRI. Ecancermedicalscience 2015 7; 9: 537..
[48]
Chen J, Carter R, Maoz D, Tobar A, Sharon E, Greif F. Breast cancer and sarcoidosis: Case series and review of the literature. Breast Care (Basel) 2015; 10(2): 137-40.
[49]
Tana C, Giamberardino MA, Di Gioacchino M, Mezzetti A, Schiavone C. Immunopathogenesis of sarcoidosis and risk of malignancy: a lost truth? Int J Immunopathol Pharmacol 2013; 26(2): 305-13.
Article Metrics
34
1